Xortx TherapeuticsXRTX
13F holders, Q1 2026 (March 31)1holders −5
1new positions
6sold out
$0.40avg. 13F price*
At the end of Q1 2026, 1 institutions reported holding Xortx Therapeutics Inc. (XRTX) in their 13F filings, down 5 from Q4 2025. 1 opened new positions and 6 sold out. The largest holder was TD Waterhouse Canada Inc. ($19).
- Company
- Xortx Therapeutics Inc.
- CUSIP
- 98420Q306
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $19 |
| Exits | 6 | $124K |
All 13F filers, Q4 2025 → Q1 2026: 47 shares bought and 230,697 shares sold, net −230,650 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| TD Waterhouse Canada Inc. | 0.00% | New | 47 | $19 |
"% of holder's portfolio" is XRTX's weight in each manager's 13F, not the share of Xortx Therapeutics Inc. the manager owns.